SEC Form SC 13D/A filed by Zivo Bioscience Inc. (Amendment)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Common Stock, $0.001 par value

(Title of Class of Securities)

98978N 101

(CUSIP Number)

Christopher D. Maggiore

4788 Nobles Pond Dr. NW

Canton, OH  44718

248-452-9866

Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

June 5, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box. ☐

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Explanatory Note:

The following constitutes Amendment No. 6 to the filing on Schedule 13D by Christopher D. Maggiore (the “Reporting Person”) originally filed with the Securities and Exchange Commission (“SEC”) on June 23, 2008, as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5 filed with the SEC by the Reporting Person, on September 26, 2018, February 27, 2019, February 19, 2020, February 14, 2023, and January 22, 2024, respectively (as amended, the “Schedule 13D”). Unless otherwise indicated, all capitalized terms used herein shall have the meanings given to them in the Schedule 13D, and unless amended or supplemented hereby, all information previously filed remains in effect.

Item 1. Security and Issuer

Item 1 of this Schedule 13D is hereby amended and restated in its entirety as follows:

This Schedule 13D filed by the Reporting Person relates to the common stock, $0.001 par value (the “Common Stock” or “Securities”), of Zivo Bioscience, Inc., a Nevada corporation the principal executive offices of which are located at 21 East Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304 (the “Company” or “Issuer”).

Item 2. Identity and Background

Item 2 of this Schedule 13D is hereby amended and restated in its entirety as follows:

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of this Schedule 13D is hereby amended and restated in its entirety as follows:

On June 5, 2024, the Reporting Person executed a Restricted Stock Award Grant Notice and agreed to cancel all of his outstanding stock options and accept a substitute grant of new equity awards under the 2021 Equity Incentive Plan of the Company. Prior to the cancellation, the Reporting Person had an aggregate 15,867 shares of the Issuer’s common stock. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock.

On June 5, 2024, the Reporting person accepted and was issued 81,544 shares of restricted stock in lieu of unpaid non-employee director service fees earned during the calendar year ending December 31, 2023. The Reporting Person was owed $53,819 and the unpaid amounts were grossed up for taxes at an assumed tax rate of 45% and the number of shares was determined based on the Issuer’s closing stock price on December 29, 2023 of $1.20 per share. Pursuant to his Restricted Stock Award Grant Notice, 50% of the granted shares vest immediately upon grant date and the remaining 50% of the shares will vest on January 1, 2025.

Item 4. Purpose of Transaction

Item 4 of this Schedule 13D is hereby amended and restated in its entirety as follows:

The Reporting Person acquired the Securities reported in this Schedule 13D as compensation for his role as a director of the Issuer.

Included in the number of Securities reported as beneficially owned by the Reporting Person are an aggregate of 3,381 shares of Common Stock issuable pursuant to warrants owned by the Reporting Person at exercise prices ranging from $38.40 to $57.60, with a weighted average exercise price of $48.00.

Other than as reported above with respect to Reporting Person’s rights to exercise warrants to acquire shares of Common Stock of the Issuer, the Reporting Person has no current plans or proposals which relate to or would result in:

Item 5. Interest in Securities of the Issuer.

Item 5 of this Schedule 13D is hereby amended and restated in its entirety as follows:

(a),(b)

The following table sets forth, as of the date of this Schedule 13D, the aggregate number and percentage of outstanding Securities which the Reporting Person may be deemed to beneficially own, as well as the number and percentage of Securities as to which the Reporting Person has or will have the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, and shared power to dispose or to direct the disposition. Securities over which the Reporting Person has or will have sole voting and sole dispositive power include (i) 454,990 shares of Common Stock owned by the Reporting Person and (ii) 3,381 shares of Common Stock issuable upon exercise of warrants owned by the Reporting Person. The percentage set forth below is based on 3,278,807 shares of Common Stock outstanding as reported in the Issuer’s Current Report on Form 8-K filed on June 6, 2024, plus 3,381 shares of Common Stock issuable upon exercise of all warrants owned by the Reporting Person.

Item 6. Contracts, Arrangements, Understandings, or Relationships with Respect to Securities of the Issuer

Item 6 of this Schedule 13D is hereby amended and restated in its entirety as follows:

Other than the Reporting Person’s relationship as a director of the Company and the warrants reported in Item 5 of this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.